• Home Dutch
  •  EN 
  • Employee login

Mutations in HSPB5, HSPB7 and BAG3 lead to juvenile DCM


Title: Mutations in HSPB5, HSPB7 and BAG3 lead to juvenile DCM.
Investigators:  post-doc (vacancy)
Promoter: HH Kampinga (PI)
Co-promoter:  BJJM Brundel (Co-PI)
Summary:   Mutations in specific heat shock proteins lead to juvenile DCM. We hypothesize that such mutations in these chaperones impairs the maintenance of protein homeostasis and thus lead to alterations in cardiomyocyte structure and contractile function. Insight in why these mutants cause DCM will help to understand how DCM arises in general. Also, it will allow testing how loss of protein homeostasis might be compensated for by boosting protein quality control and how this may help delaying disease onset. It is the aim of this project to investigate whether such events may be prevented by boosting the expression levels of (specific) heat shock proteins in cells derived from juvenile DCM patients. 
Financing:  Stichting Hartdroom, Dutch Heart Foundation, post-doc
Start:   01-09-2014
End: 01-09-2017

Organ damage and the role of CBS in hibernation.
Mechanisms and modulation of the immune response in sterile sepsis.
The CBS/H2S pathway in the brain.
Platelet dynamics in natural and pharmacologically induced hibernation.
Liver fibrosis and hibernation.
Towards prevention of neuroinflammation in major surgery.
Limiting the impact of stroke.
Identification of kinomic key proteins involved in tachycardia and stretch induced cardiomyocyte remodeling.
Role of epigenetic regulation by histone acetylation in the induction of Atrial Fibrillation.
Reversal of cardiomyocyte remodeling in Atrial Fibrillation; the role of protein degradation and translation modulators.
REVersal of cardiomyocyte structural remodeling and Improvement of functional recoVEry in Atrial Fibrillation: REVIVE.
HSF1 Activators Lower cardiomyocyte damage: towards a novel Therapeutic approach to REVERSE Atrial Fibrillation. HALT&REVERSE
Mutations in HSPB5, HSPB7 and BAG3 lead to juvenile DCM.
New therapeutic targets in diabetic kidney disease. A role of GDF-15?
Role of cyclooxygenase signalling on vascular dysfunction in the metabolic syndrome.
Vascular (Dys-)Function as a Determinant of Susceptibility to Diabetic Nephropathy: a Focus on Myogenic Constriction.